Status:

COMPLETED

Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy

Lead Sponsor:

Weill Medical College of Cornell University

Collaborating Sponsors:

Stony Brook University

Conditions:

Coronary Artery Disease

Ischemia

Eligibility:

All Genders

60-85 years

Brief Summary

The primary aim of the study is to assess and follow-up subjects that received AdGVVEGF121cDNA in IRB protocol #0794-894 entitled "Phase I Study of Direct Administration of a Replication Deficient Ade...

Detailed Description

A research coordinator from Weill Cornell Medical College will survey the medical records of all 31 subjects, and obtain contact information for all living subjects. Living subjects will be called by ...

Eligibility Criteria

Inclusion

  • Subjects for this study will be recruited from the population of subjects who participated in 2 previous Weill Cornell Medical College IRB gene transfer studies using AdGVVEGF121.10:
  • IRB protocol #0794-894 entitled "Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease" and
  • IRB protocol #0297-693 entitled "Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."

Exclusion

  • Subjects for this study will be recruited from the population of subjects who participated in 2 previous Weill Cornell Medical College IRB gene transfer studies using AdGVVEGF121.10:
  • IRB protocol #0794-894 entitled "Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease" and
  • IRB protocol #0297-693 entitled "Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."

Key Trial Info

Start Date :

May 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 1 2012

Estimated Enrollment :

31 Patients enrolled

Trial Details

Trial ID

NCT01174095

Start Date

May 1 2009

End Date

May 1 2012

Last Update

May 24 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Weill Cornell Medicine

New York, New York, United States, 10021

2

Stony Brook University Medical Center

Stony Brook, New York, United States, 11794

Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy | DecenTrialz